NYSE:JNJ
JOHNSON & JOHNSON
A diversified healthcare giant leveraging a robust pharmaceutical pipeline and ubiquitous medical device presence to deliver stable global growth.
Key Metrics
Investment Thesis
Bull Case
JNJ offers a compelling value proposition for income-focused investors seeking a defensive position in a recession-resistant sector with consistent dividend history. The company's vast pipeline in immunology and oncology, combined with its ability to generate substantial free cash flow, supports ongoing capital returns through buybacks and dividends. Its diversified revenue streams across three distinct segments provide a natural hedge against regulatory or competitive shocks in any single market.
Bear Case
The stock may underperform if the company fails to successfully launch new drugs before existing blockbuster patents expire, leading to steep revenue declines. High levels of goodwill on the balance sheet and significant accumulated other comprehensive losses could impair equity value if integration costs from recent $17.54B acquisitions exceed expectations. Furthermore, the sheer scale of the business makes it difficult to outperform smaller, more agile biotech peers in terms of growth velocity.
About JOHNSON & JOHNSON
Johnson & Johnson is a global healthcare leader operating across pharmaceuticals, medical devices, and consumer health markets. The company serves millions of patients worldwide with innovative products in immunology, oncology, neuroscience, and cardiovascular care. Its diversified portfolio spans over 60 countries, delivering consistent revenue through branded medicines and essential medical technologies.
Analysis
Management Discussion
Recent financial performance reflects a strategic rebalancing toward high-growth therapeutic areas, evidenced by revenue growth from $85.16B in 2023 to $94.19B in the latest period. While net income experienced volatility, dropping significantly in 2024 before rebounding to $26.80B, the company maintains strong operational cash flow of $24.53B to fund its $109M annual R&D spend and share repurchases. The shift from lower-margin consumer health toward higher-value innovative medicines appears to be stabilizing profitability despite macroeconomic headwinds.
Industry Overview
The global healthcare industry is characterized by rapid technological innovation and an aging population driving demand for chronic disease management solutions. Competition is intense, with major players focusing on differentiated therapies and digital health integration to capture market share. Regulatory environments vary significantly by region, requiring substantial compliance resources and influencing pricing power across international markets.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $85.16B | $88.82B | $94.19B |
| Cost of Revenue | $26.55B | $27.47B | $30.26B |
| Gross Profit | $58.61B | $61.35B | $63.94B |
| Operating Expenses | $43.54B | $44.66B | $31.36B |
| Operating Income | $15.06B | $16.69B | $32.58B |
| R&D | $483.0M | $1.84B | $109.0M |
| G&A | $21.51B | $22.87B | $23.68B |
| Stock-Based Comp | $1.16B | $1.18B | $1.35B |
| D&A | $7.49B | $7.34B | $7.50B |
| Amortization | $4.50B | $4.50B | $4.60B |
| Other OpEx | $21.55B | $19.95B | $7.57B |
| Non-Operating Income | $0 | $0 | $0 |
| Interest Expense | $772.0M | — | — |
| Interest Income | $1.26B | $1.33B | $1.06B |
| Pre-Tax Income | $15.06B | $16.69B | $32.58B |
| Income Tax | $1.74B | $2.62B | $5.78B |
| Continuing Ops | $13.33B | $14.07B | $26.80B |
| Discontinued Ops | $21.83B | $0 | $0 |
| Net Income | $35.15B | $14.07B | $26.80B |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $35.15B | $14.07B | $26.80B |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $53.49B | $55.89B | $55.62B |
| Cash & Equivalents | $21.86B | $24.11B | $19.71B |
| Marketable Securities | $1.07B | $417.0M | $393.0M |
| Accounts Receivable | $14.87B | $14.84B | $17.18B |
| Inventory | $11.18B | $12.44B | $14.19B |
| Prepaid Expenses | $4.51B | $4.08B | $4.15B |
| Other Current Assets | $0 | $0 | $0 |
| Long-Term Assets | $114.06B | $124.21B | $143.59B |
| PP&E (Net) | $19.90B | $20.52B | $23.17B |
| Intangibles | $34.17B | $37.62B | $50.40B |
| Goodwill | $36.56B | $44.20B | $48.77B |
| Operating Leases | $1.00B | $1.10B | $1.30B |
| Other LT Assets | $22.43B | $20.77B | $19.94B |
| Total Assets | $167.56B | $180.10B | $199.21B |
| Current Liabilities | $46.28B | $50.32B | $54.13B |
| Accounts Payable | $9.63B | $10.31B | $11.99B |
| Current Debt | $1.47B | $1.75B | $2.00B |
| Taxes Payable | $2.99B | $3.77B | $1.39B |
| Other Current Liab | $21.98B | $25.94B | $30.15B |
| Long-Term Liabilities | $52.50B | $58.29B | $63.54B |
| Long-Term Debt | $25.88B | $30.65B | $39.44B |
| Other LT Liab | $23.74B | $27.25B | $23.62B |
| Total Liabilities | $98.78B | $108.61B | $117.67B |
| Shareholders' Equity | $68.77B | $71.49B | $81.54B |
| Retained Earnings | $153.84B | $155.79B | $168.98B |
| AOCI | $-12.53B | $-11.74B | $-14.93B |
| Treasury Stock | $75.66B | $75.68B | $75.62B |
| Total L&E | $167.56B | $180.10B | $199.21B |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $35.15B | $14.07B | $26.80B |
| Non-Cash Adjustments | $-25.72B | $8.73B | $-8.35B |
| Working Capital Changes | $13.36B | $1.47B | $6.08B |
| Cash from Operations | $22.79B | $24.27B | $24.53B |
| Capital Expenditures | $4.54B | $4.42B | $4.83B |
| Cash from Investing | $878.0M | $-18.60B | $-23.59B |
| Debt Issuances | $0 | $6.66B | $9.14B |
| Debt Repayments | $1.55B | $1.45B | $1.76B |
| Share Buybacks | $5.05B | $2.43B | $5.95B |
| Cash from Financing | $-15.82B | $-3.13B | $-5.54B |
| FX Effect | $-112.0M | $-289.0M | $201.0M |
| Net Change in Cash | $7.73B | $2.25B | $-4.40B |
| Beginning Cash | $14.13B | $21.86B | $24.11B |
| Ending Cash | $21.86B | $24.11B | $19.71B |
Frequently Asked Questions
How does JOHNSON & JOHNSON make money?
The company's revenue is driven by three primary segments: Innovative Medicine, which generates high-margin sales from specialty drugs like Stelara and Darzalex; MedTech, providing critical surgical and orthopedic devices globally; and Consumer Health, selling over-the-counter brands such as Tylenol and Neutrogena.
What are the main risks for JNJ?
Investors should monitor potential patent cliffs on key pharmaceutical products that could impact near-term revenue streams, ongoing litigation costs related to historical talc liabilities, and the cyclical nature of medical device demand coupled with supply chain disruptions. Additionally, rising R&D expenses and strict FDA regulatory scrutiny for new drug approvals present execution risks that could compress profit margins.
What is JNJ's competitive advantage?
JNJ benefits from an extensive proprietary patent portfolio protecting its blockbuster drug franchises, a massive global distribution network ensuring market penetration, and a strong balance sheet that funds continuous R&D and acquisitions. Its dual-engine strategy of pharma and devices provides resilience against regulatory headwinds in any single sector while maintaining high barriers to entry.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.